Leonie Saft
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Leonie Saft has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Alexandar Tzankov
Institute of Medical Genetics and Pathology, University Hospital Basel and University of Basel, Basel, Switzerland
4 shared publications - Anna Green
Department of Cellular Pathology, 2nd Floor, North Wing, St Thomas’ Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
2 shared publications - Olga K. Weinberg
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications - Roos J. Leguit
Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands
2 shared publications Alexandra Traverse-Glehen
Hospices Civils de Lyon, Institut de pathologie multisite, Hôpital Lyon Sud , Lyon
1 shared publication- Alexandra Traverse-Glehen
Department of Pathology, Hospices Civils de Lyon, Lyon, France
1 shared publication
Latest Publications
- Open Access
- 14 October 2026
- Published by Elsevier in Human Pathology
Myeloid neoplasms with unusual patterns of disease evolution and progression other than acute leukemia: a European Bone Marrow Working Group workshop report
- 14 October 2026
- Published by Elsevier in Human Pathology
Open AccessMyeloid neoplasms with unusual patterns of disease evolution and progression other than acute leukemia: a European Bone Marrow Working Group workshop report
- Open Access
- 4 September 2026
- Published by Wiley in International Journal of Laboratory Hematology
ICSH Guidance on Bone Marrow Examination and Reporting
Examination of the bone marrow (BM) remains fundamental to the diagnosis, classification, prognostication, and monitoring of hematolymphoid and other disorders affecting blood cell production. Since publication of the International Council for Standardization in Haematology (ICSH) guideline in 2008, advances in diagnostic technologies, disease classification systems and laboratory reporting practices have significantly evolved. These developments necessitate a framework to support contemporary BM evaluation and reporting. This document, prepared by an international ICSH Working Party, provides updated guidance on the examination and reporting of BM specimens and is an extension and refinement of the 2008 ICSH guidelines. It outlines the appropriate application and integration of key diagnostic modalities, including morphological assessment of BM aspirate and trephine biopsy specimens, immunophenotypic analysis by flow cytometry and immunohistochemistry and molecular genetic testing. Central to this guidance is the principle of integrated reporting, whereby findings from all diagnostic modalities are synthesized within the clinical context and aligned with current international classification systems. The ICSH acknowledges the emergence of automated digital microscopy, computational decision support tools, and other technological innovations in BM analysis. These developments hold considerable promise, but whilst many remain under evaluation, specific guidance regarding their routine clinical implementation is beyond the scope of this document.
- 4 September 2026
- Published by Wiley in International Journal of Laboratory Hematology
Open AccessICSH Guidance on Bone Marrow Examination and Reporting
Examination of the bone marrow (BM) remains fundamental to the diagnosis, classification, prognostication, and monitoring of hematolymphoid and other disorders affecting blood cell production. Since publication of the International Council for Standardization in Haematology (ICSH) guideline in 2008, advances in diagnostic technologies, disease classification systems and laboratory reporting practices have significantly evolved. These developments necessitate a framework to support contemporary BM evaluation and reporting. This document, prepared by an international ICSH Working Party, provides updated guidance on the examination and reporting of BM specimens and is an extension and refinement of the 2008 ICSH guidelines. It outlines the appropriate application and integration of key diagnostic modalities, including morphological assessment of BM aspirate and trephine biopsy specimens, immunophenotypic analysis by flow cytometry and immunohistochemistry and molecular genetic testing. Central to this guidance is the principle of integrated reporting, whereby findings from all diagnostic modalities are synthesized within the clinical context and aligned with current international classification systems. The ICSH acknowledges the emergence of automated digital microscopy, computational decision support tools, and other technological innovations in BM analysis. These developments hold considerable promise, but whilst many remain under evaluation, specific guidance regarding their routine clinical implementation is beyond the scope of this document.
- Open Access
- 23 June 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-23
Reactive and therapy induced bone marrow changes linked to systemic infectious and non-infectious disorders including MAS/HLH report from the European association for haematopathology, Dubrovnik 2024
The workshop on ‘Reactive and therapy induced BM changes linked to systemic infectious and non-infectious disorders including MAS/HLH’ of the 22nd meeting of the European Association for Haematopathology held in Dubrovnik, 2024, included 58 cases. These encompassed a broad range of infections, autoimmune disorders, malignancies and therapy-effects, or a combination of these factors, of which 28 had an associated Hemophagocytic Lymphohistiocytosis (HLH) / Macrophage Activation Syndrome (MAS). Histoplasmosis, the infection mostly associated with HLH, showed a wide variability of BM changes, with or without focal lesions. Leishmaniasis, less often associated with HLH, induced BM changes that mimic myelodysplastic syndrome. BM changes after COVID-19 infection included myeloid and megakaryocytic hypoplasia, erythroid hyperplasia, dyserythropoiesis, hemophagocytosis, and possibly ring granulomas. Other infectious causes included viruses (HHV-8, EBV, Parvovirus B19), mycobacterial infections, and human granulocytic anaplasmosis. HLH may arise in association with the full spectrum of EBV-related disorders, including acute infection, systemic chronic active EBV disease, viral reactivation, and EBV-associated malignancies. BM changes associated with autoimmune diseases included plasmacytosis, myeloid hyperplasia and hemophagocytosis, with or without meeting the criteria of MAS/HLH, the latter often triggered by a secondary infection or exacerbation of the disease. Haematologic malignancies (EBV-positive and negative) with HLH encompassed B-cell, T-/NK-cell, and myeloid neoplasms. In addition, the workshop included therapy-induced BM changes, such as differentiation syndrome, lenalidomide-associated B-ALL, therapy-related dysplasia, gelatinous transformation, CAR-T–induced BM hypoplasia, and CAR-T–associated HLH. Finally, the workshop demonstrated the presence of T-cell expansions in a variety of conditions, which should not be misinterpreted as T-cell malignancy.
- 23 June 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-23
Open AccessReactive and therapy induced bone marrow changes linked to systemic infectious and non-infectious disorders including MAS/HLH report from the European association for haematopathology, Dubrovnik 2024
The workshop on ‘Reactive and therapy induced BM changes linked to systemic infectious and non-infectious disorders including MAS/HLH’ of the 22nd meeting of the European Association for Haematopathology held in Dubrovnik, 2024, included 58 cases. These encompassed a broad range of infections, autoimmune disorders, malignancies and therapy-effects, or a combination of these factors, of which 28 had an associated Hemophagocytic Lymphohistiocytosis (HLH) / Macrophage Activation Syndrome (MAS). Histoplasmosis, the infection mostly associated with HLH, showed a wide variability of BM changes, with or without focal lesions. Leishmaniasis, less often associated with HLH, induced BM changes that mimic myelodysplastic syndrome. BM changes after COVID-19 infection included myeloid and megakaryocytic hypoplasia, erythroid hyperplasia, dyserythropoiesis, hemophagocytosis, and possibly ring granulomas. Other infectious causes included viruses (HHV-8, EBV, Parvovirus B19), mycobacterial infections, and human granulocytic anaplasmosis. HLH may arise in association with the full spectrum of EBV-related disorders, including acute infection, systemic chronic active EBV disease, viral reactivation, and EBV-associated malignancies. BM changes associated with autoimmune diseases included plasmacytosis, myeloid hyperplasia and hemophagocytosis, with or without meeting the criteria of MAS/HLH, the latter often triggered by a secondary infection or exacerbation of the disease. Haematologic malignancies (EBV-positive and negative) with HLH encompassed B-cell, T-/NK-cell, and myeloid neoplasms. In addition, the workshop included therapy-induced BM changes, such as differentiation syndrome, lenalidomide-associated B-ALL, therapy-related dysplasia, gelatinous transformation, CAR-T–induced BM hypoplasia, and CAR-T–associated HLH. Finally, the workshop demonstrated the presence of T-cell expansions in a variety of conditions, which should not be misinterpreted as T-cell malignancy.
- 3 April 2026
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 165 (4)
Myeloid/lymphoid precursor cell neoplasms and mixed phenotype acute leukemias: A Bone Marrow Workshop Report from the 22nd European Association for Hematopathology/Society of Hematopathology Meeting, Dubrovnik, 2024
Objectives: The bone marrow workshop (session 3), held at the 22nd Meeting of the European Association for Hematopathology/Society of Hematopathology in Dubrovnik, was dedicated to myeloid/lymphoid precursor cell neoplasms and mixed-phenotype acute leukemias (MPALs). We hereby report the clinicopathologic, immunophenotypic, and genetic features of the submitted cases. Methods: The workshop report includes 55 cases; 37 cases represented acute myeloid leukemia (AML) and acute leukemia of ambiguous lineage. Other cases included blast phase of chronic myeloid leukemia (CML), myeloid/lymphoid neoplasms with TK gene fusions (M/LN-TK), and myelodysplastic syndrome (MDS). Additionally, cases of early T-precursor lymphoblastic leukemia (ETP-ALL) and B-precursor lymphoblastic leukemia (B-ALL) were reviewed. Results: Among acute leukemia cases, 4 of 8 with the undifferentiated phenotype were reclassified as AML, myelodysplasia related (AML-MR) due to the presence of MDS-related gene mutations or complex karyotype. Thirteen of 20 MPAL cases were reclassified as AML-MR and/or AML with mutated TP53 (fifth edition of the World Health Organization classification/International Consensus Classification). Two cases had complex karyotypes and TP53 mutations, manifesting in the postcytotoxic treatment setting. TP53 mutations were absent in immunophenotypically defined MPAL and in MPAL with BCR::ABL1. Mixed phenotypes were also described in the blast phase of M/LN-TK, CML, and MDS. Conclusions: Mixed phenotype is frequently identified in AML-MR. Future studies are needed to clarify how cases with MR gene mutations and TP53 mutations should be best classified. Additionally, MPAL, T/myeloid, and ETP-ALL and some genetically defined MPAL, B/myeloid, and B-ALL show phenotypic/genetic overlap and are challenging to diagnose. A genomic classification framework is proposed to separate AML-MR and precursor lymphoid neoplasms from MPAL.
- 3 April 2026
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 165 (4)
Myeloid/lymphoid precursor cell neoplasms and mixed phenotype acute leukemias: A Bone Marrow Workshop Report from the 22nd European Association for Hematopathology/Society of Hematopathology Meeting, Dubrovnik, 2024
Objectives: The bone marrow workshop (session 3), held at the 22nd Meeting of the European Association for Hematopathology/Society of Hematopathology in Dubrovnik, was dedicated to myeloid/lymphoid precursor cell neoplasms and mixed-phenotype acute leukemias (MPALs). We hereby report the clinicopathologic, immunophenotypic, and genetic features of the submitted cases. Methods: The workshop report includes 55 cases; 37 cases represented acute myeloid leukemia (AML) and acute leukemia of ambiguous lineage. Other cases included blast phase of chronic myeloid leukemia (CML), myeloid/lymphoid neoplasms with TK gene fusions (M/LN-TK), and myelodysplastic syndrome (MDS). Additionally, cases of early T-precursor lymphoblastic leukemia (ETP-ALL) and B-precursor lymphoblastic leukemia (B-ALL) were reviewed. Results: Among acute leukemia cases, 4 of 8 with the undifferentiated phenotype were reclassified as AML, myelodysplasia related (AML-MR) due to the presence of MDS-related gene mutations or complex karyotype. Thirteen of 20 MPAL cases were reclassified as AML-MR and/or AML with mutated TP53 (fifth edition of the World Health Organization classification/International Consensus Classification). Two cases had complex karyotypes and TP53 mutations, manifesting in the postcytotoxic treatment setting. TP53 mutations were absent in immunophenotypically defined MPAL and in MPAL with BCR::ABL1. Mixed phenotypes were also described in the blast phase of M/LN-TK, CML, and MDS. Conclusions: Mixed phenotype is frequently identified in AML-MR. Future studies are needed to clarify how cases with MR gene mutations and TP53 mutations should be best classified. Additionally, MPAL, T/myeloid, and ETP-ALL and some genetically defined MPAL, B/myeloid, and B-ALL show phenotypic/genetic overlap and are challenging to diagnose. A genomic classification framework is proposed to separate AML-MR and precursor lymphoid neoplasms from MPAL.
- Open Access
- 29 March 2025
- Published by Springer Nature in Journal of Hematopathology
- Vol. 18 (1) , 1-12
A deep-learning algorithm (AIFORIA) for classification of hematopoietic cells in bone marrow aspirate smears based on nine cell classes—a feasible approach for routine screening?
Bone marrow cytology plays a key role for the diagnosis and classification of hematological disease and is often the first step in the acute setting of unclear cytopenia. AI applications represent a powerful tool in digital image analysis and can improve the diagnostic workflow and accuracy. The aim of this study was to develop an algorithm for the automated detection and classification of hematopoietic cells in digitized bone marrow aspirate smears for potential implementation in the clinical laboratory. The AIFORIA create platform (Aiforia Technologies, Plc, Helsinki, Finland) was used to develop a convolutional neural network algorithm based on nine cell classes. Digitized bone marrow aspirate smears from normal hospital controls were used for AI training. External validation was performed on separate data sets. Automated cell classification was assessed in whole-slide images (WSI) and regions of interest (ROI). A total of 1950 single-cell annotations were applied for AI training with a final total class error of 0.15% with 99.9% precision and sensitivity (FI-score 99.2%). External validation showed an overall precision and sensitivity of 96% and 97% and a F1-score of 96%. Automated cell classification correlated highly across ROI with variable correlation to WSI. The average execution time for classifying 500 hematopoietic cells was < 1 s and ≤ 260 s for WSI. A cloud-based, deep-learning algorithm for automated detection and classification of hematopoietic cells in bone marrow aspirate smears is a very useful, reliable, and rapid screening tool in combination with cytomorphology.
- 29 March 2025
- Published by Springer Nature in Journal of Hematopathology
- Vol. 18 (1) , 1-12
Open AccessA deep-learning algorithm (AIFORIA) for classification of hematopoietic cells in bone marrow aspirate smears based on nine cell classes—a feasible approach for routine screening?
Bone marrow cytology plays a key role for the diagnosis and classification of hematological disease and is often the first step in the acute setting of unclear cytopenia. AI applications represent a powerful tool in digital image analysis and can improve the diagnostic workflow and accuracy. The aim of this study was to develop an algorithm for the automated detection and classification of hematopoietic cells in digitized bone marrow aspirate smears for potential implementation in the clinical laboratory. The AIFORIA create platform (Aiforia Technologies, Plc, Helsinki, Finland) was used to develop a convolutional neural network algorithm based on nine cell classes. Digitized bone marrow aspirate smears from normal hospital controls were used for AI training. External validation was performed on separate data sets. Automated cell classification was assessed in whole-slide images (WSI) and regions of interest (ROI). A total of 1950 single-cell annotations were applied for AI training with a final total class error of 0.15% with 99.9% precision and sensitivity (FI-score 99.2%). External validation showed an overall precision and sensitivity of 96% and 97% and a F1-score of 96%. Automated cell classification correlated highly across ROI with variable correlation to WSI. The average execution time for classifying 500 hematopoietic cells was < 1 s and ≤ 260 s for WSI. A cloud-based, deep-learning algorithm for automated detection and classification of hematopoietic cells in bone marrow aspirate smears is a very useful, reliable, and rapid screening tool in combination with cytomorphology.
- Open Access
- 12 August 2024
- Published by Taylor & Francis in Precision Oncogenomics
- Vol. 1 (1) , 1-7
Overcoming Brigatinib Resistance with Lorlatinib in Pediatric ALK Positive Anaplastic Large Cell Lymphoma with Acquired ALK p.F1174V Mutation – a Case Report
- 12 August 2024
- Published by Taylor & Francis in Precision Oncogenomics
- Vol. 1 (1) , 1-7
Open AccessOvercoming Brigatinib Resistance with Lorlatinib in Pediatric ALK Positive Anaplastic Large Cell Lymphoma with Acquired ALK p.F1174V Mutation – a Case Report
- Open Access
- 22 November 2023
- Published by Springer Nature in Die Pathologie
- Vol. 44 (S3) , 164-175
The role of flow cytometry in the classification of myeloid disorders
The World Health Organization classification (WHO-HAEM5) and the International Consensus Classification (ICC 2022) of myeloid neoplasms are based on the integration of clinical, morphologic, immunophenotypic, and genomic data. Flow cytometric immunophenotyping (FCIP) allows the identification, enumeration, and characterization of hematopoietic cells, and is therefore a powerful tool in the diagnosis, classification, and monitoring of hematological neoplasms. The vast majority of flow cytometry (FCM) studies in chronic myeloid neoplasms focus on its role in myelodysplastic neoplasms (MDS). FCM can also be helpful for the assessment of myeloproliferative neoplasms (MPN) and MDS/MPN, including the early detection of evolving myeloid or lymphoid blast crisis and the characterization of monocytic subsets. The classification of acute myeloid leukemia (AML) is primarily based on cytogenetic and molecular findings; however, FCIP is needed for subclassification of AML, not otherwise specified (NOS; ICC)/AML defined by differentiation (WHO-HAEM5). The main role of FCM in AML remains in making a rapid diagnosis and as a tool for measurable residual disease monitoring. Machine learning and artificial intelligence approaches can be used to analyze and classify FCM data. This article, based on an invited lecture at the 106th Annual Meeting of the German Society of Pathology in 2023, reviews the role of FCM in the classification of myeloid neoplasms, including recent publications on the application of artificial intelligence.
- 22 November 2023
- Published by Springer Nature in Die Pathologie
- Vol. 44 (S3) , 164-175
Open AccessThe role of flow cytometry in the classification of myeloid disorders
The World Health Organization classification (WHO-HAEM5) and the International Consensus Classification (ICC 2022) of myeloid neoplasms are based on the integration of clinical, morphologic, immunophenotypic, and genomic data. Flow cytometric immunophenotyping (FCIP) allows the identification, enumeration, and characterization of hematopoietic cells, and is therefore a powerful tool in the diagnosis, classification, and monitoring of hematological neoplasms. The vast majority of flow cytometry (FCM) studies in chronic myeloid neoplasms focus on its role in myelodysplastic neoplasms (MDS). FCM can also be helpful for the assessment of myeloproliferative neoplasms (MPN) and MDS/MPN, including the early detection of evolving myeloid or lymphoid blast crisis and the characterization of monocytic subsets. The classification of acute myeloid leukemia (AML) is primarily based on cytogenetic and molecular findings; however, FCIP is needed for subclassification of AML, not otherwise specified (NOS; ICC)/AML defined by differentiation (WHO-HAEM5). The main role of FCM in AML remains in making a rapid diagnosis and as a tool for measurable residual disease monitoring. Machine learning and artificial intelligence approaches can be used to analyze and classify FCM data. This article, based on an invited lecture at the 106th Annual Meeting of the German Society of Pathology in 2023, reviews the role of FCM in the classification of myeloid neoplasms, including recent publications on the application of artificial intelligence.
- Open Access
- 8 August 2023
- Published by Wiley in Histopathology
- Vol. 83 (6) , 829-849
Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases
Myeloid/lymphoid neoplasms with eosinophilia (M/LN‐eo) and tyrosine kinase (TK) gene fusions are a rare group of haematopoietic neoplasms with a broad range of clinical and morphological presentations. Paediatric cases have increasingly been recognised. Importantly, not all appear as a chronic myeloid neoplasm and eosinophilia is not always present. In addition, standard cytogenetic and molecular methods may not be sufficient to diagnose M/LN‐eo due to cytogenetically cryptic aberrations. Therefore, additional evaluation with fluorescence in‐situ hybridisation and other molecular genetic techniques (array‐based comparative genomic hybridisation, RNA sequencing) are recommended for the identification of specific TK gene fusions. M/LN‐eo with JAK2 and FLT3‐rearrangements and ETV6::ABL1 fusion were recently added as a formal member to this category in the International Consensus Classification (ICC) and the 5th edition of the WHO classification (WHO‐HAEM5). In addition, other less common defined genetic alterations involving TK genes have been described. This study is an update on M/LN‐eo with TK gene fusions with focus on novel entities, as illustrated by cases submitted to the Bone Marrow Workshop, organised by the European Bone Marrow Working Group (EBMWG) within the frame of the 21st European Association for Haematopathology congress (EAHP‐SH) in Florence 2022. A literature review was performed including paediatric cases of M/LN‐eo with TK gene fusions.
- 8 August 2023
- Published by Wiley in Histopathology
- Vol. 83 (6) , 829-849
Open AccessMyeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases
Myeloid/lymphoid neoplasms with eosinophilia (M/LN‐eo) and tyrosine kinase (TK) gene fusions are a rare group of haematopoietic neoplasms with a broad range of clinical and morphological presentations. Paediatric cases have increasingly been recognised. Importantly, not all appear as a chronic myeloid neoplasm and eosinophilia is not always present. In addition, standard cytogenetic and molecular methods may not be sufficient to diagnose M/LN‐eo due to cytogenetically cryptic aberrations. Therefore, additional evaluation with fluorescence in‐situ hybridisation and other molecular genetic techniques (array‐based comparative genomic hybridisation, RNA sequencing) are recommended for the identification of specific TK gene fusions. M/LN‐eo with JAK2 and FLT3‐rearrangements and ETV6::ABL1 fusion were recently added as a formal member to this category in the International Consensus Classification (ICC) and the 5th edition of the WHO classification (WHO‐HAEM5). In addition, other less common defined genetic alterations involving TK genes have been described. This study is an update on M/LN‐eo with TK gene fusions with focus on novel entities, as illustrated by cases submitted to the Bone Marrow Workshop, organised by the European Bone Marrow Working Group (EBMWG) within the frame of the 21st European Association for Haematopathology congress (EAHP‐SH) in Florence 2022. A literature review was performed including paediatric cases of M/LN‐eo with TK gene fusions.
- Open Access
- 4 March 2022
- Published by Springer Nature in Journal of Hematopathology
- Vol. 15 (1) , 13-19
Intracerebral manifestation of iatrogenic, immunodeficiency-associated polymorphic B-LPD with morphology mimicking Hodgkin lymphoma: a case report and literature review
Iatrogenic immunodeficiency-associated lymphoproliferative disorders (IA-LPD) may arise in patients treated with immunosuppressive drugs for autoimmune disease or other conditions. Polymorphic EBV-positive B-lymphoproliferations often have features mimicking Hodgkin lymphoma and typically a self-limited, indolent course. We present an unusual case with isolated, intracerebral manifestation of polymorphic B-LPD with features of classic Hodgkin-lymphoma in an immunosuppressed patient treated with methotrexate and infliximab, including clinical-radiological features and a detailed description of morphological findings, together with a literature review on reported cases of primary CNS manifestation of cHL and IA-LPD with Hodgkin-like morphology. The patient achieved complete remission following neurosurgery with gross total tumor resection and drug withdrawal without any additional treatment. Post-operative staging revealed no evidence for focal relapse or systemic disease during the 18 months follow-up period. Among the previously reported 24 cases of primary, isolated Hodgkin lymphoma in the central nervous system, three similar cases of iatrogenic, IA-LPDs were identified and are discussed here. Polymorphic B-LPD are destructive lesions with a range of morphologic features and disease manifestations. It is clinically important to recognize the spectrum of proliferations with features of classic Hodgkin lymphoma in immunodeficiency, iatrogenic settings, because they are likely to impact the choice of treatment strategies.
- 4 March 2022
- Published by Springer Nature in Journal of Hematopathology
- Vol. 15 (1) , 13-19
Open AccessIntracerebral manifestation of iatrogenic, immunodeficiency-associated polymorphic B-LPD with morphology mimicking Hodgkin lymphoma: a case report and literature review
Iatrogenic immunodeficiency-associated lymphoproliferative disorders (IA-LPD) may arise in patients treated with immunosuppressive drugs for autoimmune disease or other conditions. Polymorphic EBV-positive B-lymphoproliferations often have features mimicking Hodgkin lymphoma and typically a self-limited, indolent course. We present an unusual case with isolated, intracerebral manifestation of polymorphic B-LPD with features of classic Hodgkin-lymphoma in an immunosuppressed patient treated with methotrexate and infliximab, including clinical-radiological features and a detailed description of morphological findings, together with a literature review on reported cases of primary CNS manifestation of cHL and IA-LPD with Hodgkin-like morphology. The patient achieved complete remission following neurosurgery with gross total tumor resection and drug withdrawal without any additional treatment. Post-operative staging revealed no evidence for focal relapse or systemic disease during the 18 months follow-up period. Among the previously reported 24 cases of primary, isolated Hodgkin lymphoma in the central nervous system, three similar cases of iatrogenic, IA-LPDs were identified and are discussed here. Polymorphic B-LPD are destructive lesions with a range of morphologic features and disease manifestations. It is clinically important to recognize the spectrum of proliferations with features of classic Hodgkin lymphoma in immunodeficiency, iatrogenic settings, because they are likely to impact the choice of treatment strategies.
- Open Access
- 25 August 2016
- Published by Springer Nature in Annals of Hematology
- Vol. 95 (11) , 1825-1832
TERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations
The telomerase reverse transcriptase (TERT) gene rs2736100_C allele has recently been shown to be associated with an increased risk for myeloproliferative neoplasms (MPNs) among Caucasians. However, it is unknown if this association is present in other ethnical populations and whether rs2736100 allele frequencies mirror the incidence of MPNs in a population. Here we genotyped TERT rs2736100 variants in 126 Swedish and 101 Chinese MPN patients and their age-, sex-, and ethnically-matched healthy controls. Healthy Chinese adults had a higher frequency of the A allele and lower frequencies of the C allele compared to Swedish counterparts (57.4 vs 47.0 % for A, 42.6 vs 53.0 % for C, P = 0.006). Both Swedish and Chinese patients harbored significantly higher C allele frequency than their controls (62.7 vs 53.0 % and 57.4 vs 42.6 % for Swedish and Chinese, respectively, P = 0.004). Swedes and Chinese bearing the CC genotype had a significantly increased risk of MPN compared to AA carriers (OR = 2.47; 95 % CI: 1.33–4.57, P = 0.003, for Swedes, and OR = 3.45; 95 % CI: 1.52–7.85, P = 0.005, for Chinese). Further analyses showed that rs2736100_CC was associated with robustly enhanced risk in males only (CC vs AA, OR = 5.11; 95 % CI: 2.19–11.92, P < 0.0001). The CC-carrying MPN patients exhibited significantly higher TERT expression than patients with the AC genotype. Collectively, the rs2736100_C is a risk allele for MPNs in Swedish and Chinese males, and the lower incidence of MPNs in the Chinese population is correlated with a lower rs2736100_C risk allele frequency.
- 25 August 2016
- Published by Springer Nature in Annals of Hematology
- Vol. 95 (11) , 1825-1832
Open AccessTERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations
The telomerase reverse transcriptase (TERT) gene rs2736100_C allele has recently been shown to be associated with an increased risk for myeloproliferative neoplasms (MPNs) among Caucasians. However, it is unknown if this association is present in other ethnical populations and whether rs2736100 allele frequencies mirror the incidence of MPNs in a population. Here we genotyped TERT rs2736100 variants in 126 Swedish and 101 Chinese MPN patients and their age-, sex-, and ethnically-matched healthy controls. Healthy Chinese adults had a higher frequency of the A allele and lower frequencies of the C allele compared to Swedish counterparts (57.4 vs 47.0 % for A, 42.6 vs 53.0 % for C, P = 0.006). Both Swedish and Chinese patients harbored significantly higher C allele frequency than their controls (62.7 vs 53.0 % and 57.4 vs 42.6 % for Swedish and Chinese, respectively, P = 0.004). Swedes and Chinese bearing the CC genotype had a significantly increased risk of MPN compared to AA carriers (OR = 2.47; 95 % CI: 1.33–4.57, P = 0.003, for Swedes, and OR = 3.45; 95 % CI: 1.52–7.85, P = 0.005, for Chinese). Further analyses showed that rs2736100_CC was associated with robustly enhanced risk in males only (CC vs AA, OR = 5.11; 95 % CI: 2.19–11.92, P < 0.0001). The CC-carrying MPN patients exhibited significantly higher TERT expression than patients with the AC genotype. Collectively, the rs2736100_C is a risk allele for MPNs in Swedish and Chinese males, and the lower incidence of MPNs in the Chinese population is correlated with a lower rs2736100_C risk allele frequency.